drugset
drugset / Trial / NCT02206568

Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus

NCT02206568 ↗

Phase 1 Withdrawn AMAG Pharmaceuticals, Inc. Profil Institut für Stoffwechselforschung GmbH · collab
NaSingle-groupTriple-blindBasic science

Summary

To compare the early pharmacokinetic exposure of URAL and insulin lispro (ILisp).

Timeline

Start
2014-06
Primary completion
2014-08
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject URAL Unknown — —

Indications

type 1 diabetes mellitus